Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
Kausik Ray, Professor of Public Health at Imperial College London, Past President of European Atherosclerosis Society, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in JACC Journals, adding:
“Ruvonoflast reduced hsCRP in patients with elevated inflammatory risk.
We just published the phase 1 data.
Ongoing Phase 2 trials.”
Title: Anti-inflammatory effects of oral NLRP3 inhibition with ruvonoflast among individuals at elevated cardiovascular risk
Authors: Kausik K. Ray, Nicholas Clarke, Peter Thornton, Amy E. Miles, Zsofia Digby, Melanie J. Davies, Michelle Gorman, Bianca Mullen, Valérie Reader, Missy Magill, Hilary Johnstone, Cono Ariti, Naveed Sattar, Nikolaus Marx, Ann Marie Navar, Adrian F. Hernandez, Jyothis T. George, Alan P. Watt, Javed Butler, Paul M. Ridker
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026
-
Jul 13, 2026, 17:39Pascal Boulanger: Send a Postcard to Your Lab Staff From ISTH 2026
-
Jul 13, 2026, 17:21Stefano Navarro: Presenting Our Recently Published Article at ISTH 2026